Company Information

  

Address: 642 NEWTOWN YARDLEY ROAD  
City: NEWTOWN 
State: PA 
Zip Code: 18940 
Telephone: 215-944-6104 

Description of Business

Primary SIC Code: 3845
(As filed with the SEC)  

We are a neurotechnology company focused on neurological wellness. Our purpose is to develop, license or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. Our first product, the Portable Neuromodulation Stimulator, or PoNS(TM), is an authorized medical device in Canada for the treatment of chronic balance deficit associated with a mild to moderate traumatic brain injury, or mmTBI, and is an investigational, non-invasive, medical device for which we have submitted an application for marketing authorization to the U.S. Food and Drug Administration, or FDA, and for a CE mark in the European Union, or EU, to improve balance in patients following a mmTBI. Our PoNS device, when combined with targeted physical and/or cognitive therapy, or the PoNS Treatment, is the first and only patented treatment that combines neurostimulation of cranial nerves via the tongue to restore lost function.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2019-0.37NAN/E
06/2019-0.32NAN/E
03/2019-1.24NAN/E
12/2018-1.26NAN/E
09/2018-1.24NAN/E
06/2018-1.77NAN/E
03/2018-1.26NAN/E
12/2017--NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2018 Leverage 2018
Net Inc/Comm Equity-0.27Total Liab/Total Assets0.65
Net Inc/Total Assets-1.03Total Liab/Inv Cap-4.59
Net Inc/Inv Cap7.31Total Liab/Comm Equity0.17
Pretax Inc/Net Sales-59.88Interest Coverage RatioNA
Net Inc/Net Sales-59.88Curr Debt/Equity1.40
Cash Flow/Net Sales-41.05LTD/EquityNA
SG&A/NetSales36.01Total Debt/Equity1.40
Asset Utilization   Liquidity  
Net Receivables Turnover0.98Quick Ratio1.48
Inventory TurnoverNACurrent Ratio1.50
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.05Inv/Curr Assets0.01
Net Sales/PP&E0.86  

Income Statement (Millions)

  9/30/2019 6/30/2019 3/31/2019 12/31/2018
Total Revenues(Net Sales) 0.15 0.52 0.68 0.48
Cost of Goods Sold 0.09 0.21 0.24 0.00
Selling & Admin Exps 4.29 3.85 4.58 3.58
Operating Income -5.74 -5.81 -6.82 -5.26
Interest Exp NA NA NA NA
Pretax Income -5.59 -0.19 1.32 -5.12
Other Income 0.15 5.63 8.15 0.15
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -5.59 -0.19 1.32 -5.12

Balance Sheet (Millions)

Assets 9/30/2019 6/30/2019 3/31/2019 12/31/2018
Cash & Short Term Investments 9.02 14.31 18.66 25.58
Receivables - Total 0.76 1.01 1.09 0.28
Inventories - Total 1.29 0.90 0.73 0.39
Total Current Assets 11.23 16.53 20.83 26.96
Net Property, Plant & Equipment 1.31 1.33 1.34 0.55
Total Assets 12.88 18.20 22.50 27.83
Liabilities        
Accounts Payable 3.30 4.42 3.99 4.20
Debt in Current Liabilities 0.08 0.28 5.74 13.77
Total Current Liabilities 3.55 4.86 9.88 17.97
Long-Term Debt NA NA NA NA
Total Liabilities 4.06 5.42 10.48 17.97
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.03 0.03 0.03
Retained Earnings -99.44 -93.85 -93.67 -94.99
Treasury Stock NA NA NA NA
Total Stockholders' Equity 8.82 12.78 12.02 9.85
Total Liabilities and Stockholders' Equity 12.88 18.20 22.50 27.83

Cash Flow Summary (Millions)

Categories 9/30/2019 6/30/2019 3/31/2019 12/31/2018
Net Cash Provided by Operating Activities -5.25 -4.41 -6.80 -5.15
Net Cash Provided by Investing Activities -0.06 -0.04 -0.16 -0.02
Net Cash Provided by Financing Activities 0.00 0.12 0.04 18.34

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20140.00-1.07--
12/20150.00-9.84--
12/20160.00-12.04--
12/20170.00-28.02--
12/20180.48-28.62-1.26
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/19441,6415.34




Report Date : 12/2/2019

Powered By Edgar Online © 2019EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.